Company Overview

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development, commercialization, and lifecycle management of therapeutics primarily for gastrointestinal (GI) and infectious disease indications. The company operates within the biopharmaceutical and specialty pharmaceuticals industries, with an emphasis on late-stage clinical development and marketed products addressing conditions with significant unmet medical need. Its business model combines in-house development with the acquisition or in-licensing of assets that can be advanced through regulatory approval and commercialization.

RedHill’s primary revenue drivers have historically included branded prescription drugs in the GI space, notably therapies for Helicobacter pylori infection and traveler’s diarrhea. The company is positioned as a niche GI-focused pharmaceutical firm, leveraging targeted sales infrastructure and clinical expertise rather than large-scale primary care marketing. Founded in 2009 and headquartered in Israel, RedHill has evolved from a development-stage biotech into a commercial-stage company, though its trajectory has included restructuring efforts and capital constraints as it sought to sustain U.S. commercial operations.

Business Operations

RedHill’s operations are organized around the development and commercialization of proprietary and licensed pharmaceutical products. Its key commercial products have included Talicia® (for H. pylori infection) and Aemcolo® (rifamycin SV-MMX®, for noninvasive strains of E. coli in traveler’s diarrhea). These products have been marketed primarily in the United States, supported by a dedicated GI-focused sales force. Revenue generation has largely depended on prescription sales, supplemented at times by licensing or distribution arrangements.

The company has conducted research and development activities through internal teams and external contract research organizations, focusing on late-stage clinical programs and post-approval lifecycle management. RedHill operates through subsidiaries, most notably RedHill Biopharma Inc., its U.S.-based commercial arm. Public disclosures indicate that the U.S. subsidiary entered Chapter 11 bankruptcy proceedings as part of a financial restructuring process, while the parent company continued to manage strategic assets and intellectual property. Data inconclusive based on available public sources regarding the current scale of active commercial operations following restructuring.

Strategic Position & Investments

Strategically, RedHill has sought to concentrate resources on GI and infectious disease assets with defined regulatory pathways and commercial potential in specialty markets. Growth initiatives have included advancing clinical-stage pipeline candidates, pursuing additional indications for existing products, and seeking regional licensing partnerships to monetize assets outside the United States. The company has also emphasized cost containment and balance sheet restructuring as part of its near-term strategy.

RedHill’s portfolio has included development-stage programs such as RHB-104 for Crohn’s disease and RHB-204 for pulmonary nontuberculous mycobacterial infections, reflecting continued interest in inflammatory and infectious disorders. Investment activity has been selective, with a focus on internal pipeline progression rather than large-scale acquisitions. Where disclosures differ on the status or prioritization of specific pipeline assets, data is inconclusive based on available public sources.

Geographic Footprint

RedHill Biopharma is headquartered in Israel, with historical operational and commercial activities centered in the United States, which has represented its most significant market. The U.S. has been the primary geography for product launches, clinical trials, and regulatory engagement with the U.S. Food and Drug Administration (FDA).

Beyond Israel and the United States, RedHill has maintained an international footprint through licensing arrangements, clinical trial sites, and third-party manufacturing and distribution relationships. Its market presence outside North America has generally been opportunistic rather than supported by owned commercial infrastructure, with influence extending into parts of Europe and other regions through partners rather than direct operations.

Leadership & Governance

RedHill was founded by Dr. Jonathan Rigby, who previously served as Chairman and CEO and played a central role in shaping the company’s GI-focused strategy and acquisition-led growth model. The company is currently led by an executive team responsible for navigating commercialization, pipeline development, and financial restructuring while maintaining compliance with public company governance standards.

Key members of leadership have included:

• Dror Ben-Asher – Chief Executive Officer
• Roni Ben-Yehuda – Chief Financial Officer
• Dr. Ohad Amitay – Chief Medical Officer
• Yehudit Pardess – Head of Research and Development

The leadership philosophy has emphasized disciplined capital allocation, focus on core therapeutic areas, and the advancement of differentiated assets through regulatory milestones. Governance is overseen by a board of directors with experience in pharmaceuticals, finance, and biotechnology, consistent with requirements for a Nasdaq-listed company.